{"id":"https://openalex.org/W1985353051","doi":"https://doi.org/10.1097/00004714-199510000-00003","title":"Coadministration of Nefazodone and Benzodiazepines: II. A Pharmacokinetic Interaction Study With Triazolam","display_name":"Coadministration of Nefazodone and Benzodiazepines: II. A Pharmacokinetic Interaction Study With Triazolam","alternate_titles":[],"publication_year":1995,"publication_date":"1995-10-01","ids":{"openalex":"https://openalex.org/W1985353051","doi":"https://doi.org/10.1097/00004714-199510000-00003","mag":"1985353051","pmid":"https://pubmed.ncbi.nlm.nih.gov/8830062"},"language":"en","primary_location":{"id":"doi:10.1097/00004714-199510000-00003","doi":"https://doi.org/10.1097/00004714-199510000-00003","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004714-199510000-00003","pdf_url":null,"source":{"id":"https://openalex.org/S76849566","display_name":"Journal of Clinical Psychopharmacology","issn_l":"0271-0749","issn":["0271-0749","1533-712X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1985353051"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108807818","display_name":"Rashmi H. Barbhaiya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Rashmi H. Barbhaiya","raw_affiliation_strings":["Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, USA","(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111886966","display_name":"Umesh Shukla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Umesh A. Shukla","raw_affiliation_strings":["(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068273065","display_name":"Patricia Dowley Kroboth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Patricia D. Kroboth","raw_affiliation_strings":["(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079233115","display_name":"Douglas S. Greene","orcid":"https://orcid.org/0000-0003-3582-6139","observed_orcids":["https://orcid.org/0000-0003-3582-6139"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Douglas S. Greene","raw_affiliation_strings":["(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(Barbhaiya, Shukla, Greene) Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Princeton, New Jersey and (Kroboth) The Pharmacodynamic Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; Address requests for reprints to: Rashmi H. Barbhaiya, PhD, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543-4000.; Received December 2, 1994 and accepted May 9, 1995","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5108807818"],"corresponding_institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210091812"],"apc_list":null,"apc_paid":null,"fwci":7.8398,"has_fulltext":false,"cited_by_count":103,"citation_normalized_percentile":{"value":0.98316832,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"15","issue":"5","first_page":"320","last_page":"326"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nefazodone","display_name":"nefazodone","score":0.972000002861023},{"id":"https://openalex.org/keywords/triazolam","display_name":"triazolam","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.656000018119812},{"id":"https://openalex.org/keywords/cyp3a4-inhibition","display_name":"CYP3A4 inhibition","score":0.9539999961853027},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8299999833106995},{"id":"https://openalex.org/keywords/m-chlorophenylpiperazine","display_name":"m-chlorophenylpiperazine","score":0.984000027179718},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.39800000190734863},{"id":"https://openalex.org/keywords/benzodiazepines","display_name":"benzodiazepines","score":0.9580000042915344},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6190000176429749}],"concepts":[{"id":"https://openalex.org/C2779419675","wikidata":"https://www.wikidata.org/wiki/Q416632","display_name":"Nefazodone","level":5,"score":0.9910621643066406},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4403670132160187},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37315768003463745},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.14526638388633728},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.11319956183433533},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001711","descriptor_name":"Biotransformation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006899","descriptor_name":"Mixed Function Oxygenases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014229","descriptor_name":"Triazolam","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014229","descriptor_name":"Triazolam","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004714-199510000-00003","doi":"https://doi.org/10.1097/00004714-199510000-00003","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004714-199510000-00003","pdf_url":null,"source":{"id":"https://openalex.org/S76849566","display_name":"Journal of Clinical Psychopharmacology","issn_l":"0271-0749","issn":["0271-0749","1533-712X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:8830062","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8830062","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical psychopharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W36420567","https://openalex.org/W129676232","https://openalex.org/W1655524691","https://openalex.org/W1859882522","https://openalex.org/W1958017720","https://openalex.org/W1970864557","https://openalex.org/W1972214008","https://openalex.org/W1979886938","https://openalex.org/W1980243334","https://openalex.org/W1982722480","https://openalex.org/W1984291639","https://openalex.org/W1986766832","https://openalex.org/W1989090483","https://openalex.org/W1997974463","https://openalex.org/W2004576165","https://openalex.org/W2016311788","https://openalex.org/W2032888832","https://openalex.org/W2038310336","https://openalex.org/W2042033252","https://openalex.org/W2049668649","https://openalex.org/W2067145171","https://openalex.org/W2068769565","https://openalex.org/W2072897211","https://openalex.org/W2074116043","https://openalex.org/W2093704573","https://openalex.org/W2110924339","https://openalex.org/W2168265602","https://openalex.org/W2230160214","https://openalex.org/W4252990426"],"related_works":["https://openalex.org/W2460310820","https://openalex.org/W2313908245","https://openalex.org/W2163639550","https://openalex.org/W2079367118","https://openalex.org/W2316767766","https://openalex.org/W2082486724","https://openalex.org/W2162946847","https://openalex.org/W2130008321","https://openalex.org/W2133124491","https://openalex.org/W1985419749"],"abstract_inverted_index":{"This":[0],"study":[1,34,65],"was":[2,66,109,206,227,259,291,296],"conducted":[3,67],"to":[4,57,68,83,119,254,282,313,316],"determine":[5],"the":[6,70,76,114,120,135,139,152,162,181,212,220,239,273,317,335],"potential":[7,71],"for":[8,72,161,180,345],"an":[9,59,73,90],"interaction":[10,74],"between":[11,75],"nefazodone,":[12,215,266,331],"a":[13,19,30,167,194,228,332],"new":[14],"antidepressant,":[15],"and":[16,24,49,88,104,144,159,174,178,185,190,224,262,299],"triazolam":[17,23,42,100,131,165,210,223,244,258,270,290,295,308,327,336],"after":[18,219],"single":[20],"dose":[21,92,137],"of":[22,27,41,61,85,93,99,116,122,130,141,154,164,183,209,214,222,231,234,241,289,319],"multiple":[25],"doses":[26],"nefazodone":[28,51,136,184,235],"in":[29,35,55,263,307,310,334],"randomized,":[31],"double-blind,":[32],"placebo-controlled":[33],"healthy":[36],"male":[37],"volunteers.":[38],"The":[39,285,305],"metabolism":[40,323],"is":[43,328,338,343],"dependent":[44],"on":[45,101,138,151,175,211,238],"cytochrome":[46,320],"P450":[47,321],"3A4,":[48],"because":[50],"has":[52],"been":[53],"shown":[54],"vitro":[56],"be":[58,314],"inhibitor":[60],"this":[62,64],"isoenzyme,":[63],"assess":[69],"two":[77,86],"drugs.":[78],"Twelve":[79],"subjects":[80],"were":[81,149],"assigned":[82],"one":[84],"groups":[87],"received":[89,126],"oral":[91],"either":[94,127],"placebo":[95,133],"or":[96,132,217],"0.25":[97,128],"mg":[98,129,233],"days":[102,142,155,176],"1":[103],"2.":[105],"Nefazodone":[106],"(200":[107],"mg)":[108],"administered":[110,260],"twice":[111,236],"daily":[112,237],"from":[113,252,280],"evening":[115],"day":[117,123],"2":[118],"morning":[121],"9.":[124,145],"Subjects":[125],"with":[134,265,303,330],"mornings":[140,153],"8":[143,177],"Serial":[146],"blood":[147],"samples":[148],"collected":[150],"1,":[156],"2,":[157],"8,":[158],"9":[160,179],"analysis":[163,182,202],"by":[166,193,324],"validated":[168,195],"gas":[169],"chromatography/electron":[170],"capture":[171],"detection":[172],"method":[173],"its":[186],"metabolites,":[187],"hydroxynefazodone":[188],"(HO-nefazodone)":[189],"m-chlorophenylpiperazine":[191],"(mCPP),":[192],"high-performance":[196],"liquid":[197],"chromatography/ultraviolet":[198],"method.":[199],"Noncompartmental":[200],"pharmacokinetic":[201],"showed":[203],"that":[204],"there":[205],"no":[207,340],"effect":[208,230],"pharmacokinetics":[213,240],"HO-nefazodone,":[216],"mCPP":[218],"coadministration":[221],"nefazodone.":[225,304,325,346],"There":[226],"significant":[229],"200":[232],"triazolam.":[242],"Mean":[243],"peak":[245],"concentration":[246],"values":[247,275],"increased":[248,276],"(p":[249,277],"=":[250],"0.003)":[251],"2.33":[253],"3.88":[255],"ng/ml":[256],"when":[257,294,300],"alone":[261,298],"combination":[264],"respectively.":[267],"Corresponding":[268],"mean":[269],"area":[271],"under":[272],"curve":[274],"<":[278],"0.001)":[279],"8.14":[281],"31.74":[283],"ng.h/ml.":[284],"plasma":[286,311],"protein":[287],"binding":[288],"approximately":[292],"85%":[293],"given":[297,301],"concurrently":[302],"increase":[306],"concentrations":[309],"appears":[312],"attributable":[315],"inhibition":[318],"3A4":[322],"If":[326],"coadministered":[329],"reduction":[333],"dosage":[337,341],"recommended;":[339],"adjustment":[342],"required":[344]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1985353051","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
